<img src="https://ws.zoominfo.com/pixel/eCRg8hzy2qp0kNUl6E1g" width="1" height="1" style="display: none;">


Press Releases

Our latest announcements

Biodesix Named To Inc. 500|5000 Fastest-Growing Private Companies List

Biodesix named to Inc. 500|5000 Fastest-Growing Private Companies list

Biodesix Adds Biognosys’ Proteomics Technology To Its Diagnostic Development Capabilities; Collaboration Enables Protein Identification Within Proteomic Signatures

Biodesix recently added Biognosys' Proteomics to their capabiltites.

Health Net, Inc. Provides Coverage for Biodesix’ VeriStrat Test 

HealthNet now covers Biodesix' VeriStrat test

Biodesix Raises Follow-On Series E Financing

Biodesix raises follow-on series E financing

Aetna Provides Coverage for Biodesix’ VeriStrat Test

Biodesix announced that the VeriStrat® test is now considered a medically necessary benefit by Aetna Corporation.

Biodesix Receives Positive Coverage from Cigna for VeriStrat Test

Biodesix' VeriStrat test is covered by Cigna

Biodesix Receives CareFirst BlueCross BlueShield (BCBS) Coverage for VeriStrat Test

Biodesix' VeriStrat test has won approval from CareFirst BlueCross BlueShield

Lung Cancer Journal: VeriStrat Proteomic Test Improves Overall Survival and Decreases Medical Costs for Patients with Advanced NSCLC

The paper’s authors conclude that using VeriStrat improves overall survival and decreases medical costs in the US payer system.

Biodesix And Inivata To Investigate Clinical Utility Of Next Generation Sequencing-Blood Based Tests For Patients With Advanced Lung Cancer

Biodesix, Inc and Inivata announced a partnership today to develop and commercialize Next Generation Sequencing (NGS)-blood based tests for lung cancer.

Biodesix Raises Additional Series E Financing

In addition to the $15 million of series shares in 2013 and 2014, Biodesix brought in another $12 million, for total proceeds of $27 million from the sale.